Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026

Molecular Partners AG announced it will present data on its lead Radio-DARPin candidate MP0712, co-developed with Orano Med, at two major scientific conferences in November and December 2026. The presentations will include initial dose escalation data from a Phase 1/2a study in small cell lung cancer and other DLL3-expressing solid tumors, with efficacy data expected in the coming months.